Chronic kidney disease trials in Israel

In Israel 9 Also abroad 798

9 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Where
Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Rehovot, Tel Aviv, Tiberias
Age
18 years and over
People
5,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT06742723 · EU 2023-506460-14-00
Phase 3Taking people
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Where
Ashdod, Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Rehovot, Safed, Sakhnin, Tel Aviv, Tsrifin
Age
50 years and over
People
7,140 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07241390 · EU 2025-523123-22-00
No phaseEnrolling by invitation
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
Where
Haifa
Age
0 Minutes to 2 weeks
People
8,000 worldwide
Run by
Indiana University
See details and how to joinNCT06823115
Phase 2Taking people
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Where
Jerusalem, Petah Tikva
Age
12 years to 18 years
People
18 worldwide
Run by
Vifor Fresenius Medical Care Renal Pharma
See details and how to joinNCT06593392 · EU 2023-509909-74-00
Phase 3Taking people
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Where
Ashkelon, Jerusalem, Petah Tikva
Age
18 years to 100 years
People
540 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00
Phase 3Taking people
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Where
Beersheba, Jerusalem, Nahariya, Petah Tikva, Tel Aviv
Age
1 year to 18 years
People
100 worldwide
Run by
Bayer
See details and how to joinNCT05457283 · EU 2023-504885-50-00
Phase 2/3Taking people
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Where
Afula, Ashkelon, Haifa, Holon, Nahariya, Petah Tikva, Ramat Gan, Rehovot, Safed, Tel Aviv, Tiberias
Age
18 years and over
People
3,110 worldwide
Run by
CSL Behring
See details and how to joinNCT05485961 · EU 2022-500273-14-00
Phase 3Taking people
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Where
Ashkelon, Be’er Ya‘aqov, Hadera, Haifa, Holon, Kfar Saba, Nahariya, Ramat Gan, Rehovot, Tiberias
Age
18 years and over
People
7,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT07753993 · EU 2025-523994-41-00
No phaseTaking people
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
Where
Jerusalem, Kfar Saba, Ramat Gan, Tel Aviv
Age
18 years and over
People
3,600 worldwide
Run by
The University of Queensland
See details and how to joinNCT03573089